medicinetoday.com
Jan 27, 2025, 10:10
Yianni Kournoutas: 1st Line Atezolizumab/Bevacizumab vs. Tremelimumab/Durvalumab in Unresectable HCC
Yianni Kournoutas, Hematologist and Oncologist at Mayo Clinic shared a post on X:
“Great time at GI25, GIASCO so far! Had a blast presenting our study on 1st line atezo/bev vs. treme/durva in unresectable HCC.
Many thanks to my mentors Dr. Tran Nguyen and Dr. Ou for their support and guidance.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 19, 2025, 21:04
Apr 19, 2025, 20:48
Apr 19, 2025, 20:25
Apr 19, 2025, 19:36
Apr 19, 2025, 19:17
Apr 19, 2025, 19:01
Apr 19, 2025, 18:42
Apr 19, 2025, 18:29